Dianthus Therapeutics Inc. 宣布,其独立数据安全监查委员会(DSMB)的审查结果已确认试验可继续推进。此次审查确认,试验过程中未出现任何与治疗方案相关的严重感染或不良事件。
这一积极结果进一步支持了该临床试验的安全性评估,为后续研究阶段的顺利开展奠定了坚实基础。
Dianthus Therapeutics Inc. 宣布,其独立数据安全监查委员会(DSMB)的审查结果已确认试验可继续推进。此次审查确认,试验过程中未出现任何与治疗方案相关的严重感染或不良事件。
这一积极结果进一步支持了该临床试验的安全性评估,为后续研究阶段的顺利开展奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.